Elephas Demonstrates elive™ Platform Measures Cytotoxicity in Targeted Therapies, Expanding Functional Precision Medicine Reach
核心洞察
Elephas Biosciences (搜索) presented new AACR D3 data showing its elive platform can now measure response to targeted therapies in addition to immune checkpoint inhibitors.
Ex vivo treatment with daraxonrasib showed similar cytotoxic effects in both mouse xenografts and live human tumor fragments, validating translational performance.
The milestone coincides with ASCO issuing a clinical notice formally affirming functional precision medicine as a meaningful path forward in cancer (搜索) care.
Elephas Biosciences (搜索) Corporation announced new data at the American Association for Cancer (搜索) Research Drug Discovery and Development (AACR D3) conference demonstrating that its elive™ platform can now measure cytotoxicity endpoints in targeted therapies, extending beyond its previously established capability with immune checkpoint inhibitors (ICIs). The development marks a significant expansion of the platform's utility across two of oncology's most important therapeutic modalities.
The poster, titled "Evaluation of immune checkpoint inhibitors and targeted therapies ex vivo in live tumor fragments from core biopsies and resections accurately predicts response in the clinic," was presented by Sean Caenepeel, Vice President of Medical Affairs at Elephas. Data were generated from mouse xenografts and live tumor fragments derived from a human specimen. Ex vivo treatment with daraxonrasib exhibited similar cytotoxic effects in both models, providing a strong signal that the platform's performance translates from preclinical models to patient tissues.
ASCO Endorsement Adds Momentum
The data arrive at a pivotal moment for functional precision medicine. The presentation came shortly after the American Society of Clinical Oncology (ASCO) issued a clinical notice formalizing its support for functional precision medicine as a meaningful path forward in cancer (搜索) care. Together, these developments signal that ex vivo functional testing is moving from a promising concept toward a future tool for guiding real-world treatment decisions.
"ASCO's notice reflects real momentum toward more personalized cancer (搜索) care," said Maneesh Arora, founder and CEO of Elephas. "Our prior data show that functional testing on live tumor tissue can predict response to immunotherapy. The elive platform now has the potential to profile response to targeted therapies as well. Elephas is proud to be one of the only companies with data supporting functional precision medicine across both treatment classes, and we're energized to help shape what comes next for oncology diagnostics."
Addressing an Unmet Need in Oncology
Cancer (搜索) remains a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite a significant increase in the number of available immunotherapies, only one in five patients receiving immunotherapy obtains a response, and many who may respond are not eligible for therapy due to a lack of accurate predictive biomarkers. The elive platform addresses this challenge by preserving the native tumor microenvironment from a live core needle biopsy and employing a novel method to account for tumor heterogeneity, enabling real-time characterization of immune response.
The platform's expansion into targeted therapies broadens its potential clinical impact, offering the possibility of functional testing that spans both major oncology treatment classes. Elephas, a private company based in Madison, Wisconsin, continues to advance its mission of tackling the growing dilemma of treatment response prediction in an era of expanding therapeutic options.